Clinics Across Florida, New Jersey & California Advancing Mental Health in Underserved Communities – Awarded Funding from Teva Pharmaceuticals, Direct Relief and NAFC
Community Routes: Access to Mental Healthcare, a partnership between Direct Relief, the National Association of Free and Charitable Clinics, and Teva Pharmaceuticals, provides awards to support clinics expanding access to mental health services across three states
SANTA BARBARA, Calif. & PARSIPPANY, N.J.--(BUSINESS WIRE)-- Teva Pharmaceuticals, the National Association of Free and Charitable Clinics (NAFC) and Direct Relief announced today – as part of a two-year, $2 million commitment – the awarding of $825,000 in grant funding for 11 free and charitable clinics addressing mental health across Florida, New Jersey and California.
The grant awardees were selected for their innovative and practical approaches to mental health care, which include efforts to expand healthcare access for underserved and vulnerable patients experiencing mental and behavioral health issues, with a focus on depression and anxiety.
“The free and charitable clinics chosen for this initiative are already providing outstanding care in their communities, and this funding, generously provided by Teva, will allow them to do even more, by expanding life-saving mental health care to those who need it most,” said Thomas Tighe, CEO and President of Direct Relief.
In addition to funding, Teva is making a broad portfolio of generic mental health medications available on a charitable basis.
”Teva is proud to partner with Direct Relief and the National Association of Free and Charitable Clinics on Community Routes: Access to Mental Health Care, a novel health equity initiative aiming to expand access to healthcare services for underserved populations,” added Dr. Sven Dethlefs, Executive Vice President, North America Commercial. “At Teva, we know how critical it is to enable access to medicines that help improve people’s lives and look forward to seeing how these local clinics create or expand needed programs that drive real impact for patients.”
Anxiety and depression disorders affect more than 40 million adults in the U.S. annually. Additionally, 84 percent of physicians reported an increase in new diagnoses of mental health conditions since the pandemic began, especially among racial and ethnic minorities and lower-income households, according to a recent nationwide survey by the Morehouse School of Medicine and Teva Pharmaceuticals.
“Through this program, clinics will be able to enhance and expand access to crucial mental health services for their communities,” said Nicole Lamoureux, President and CEO of NAFC. “The NAFC is grateful that Direct Relief and Teva Pharmaceuticals not only recognize the barriers to care communities often face and the importance of mental health care, but that they also are taking steps to join with the NAFC and support our clinics on the ground to provide solutions and increased access to care.”
The 2022 winners are:
- University of Florida Mobile Outreach in Gainesville, Florida - Creates and disseminates evidence-informed, easily accessible mental health wellness curriculum to underserved populations via trusted community members through a mobile outreach model.
- Grace Medical Home in Orlando, Florida - Expands an existing program that proactively identifies trauma and offers individualized interventions through an integrated, whole-person, multi-disciplinary approach to improve health outcomes.
- Talbot House Ministries of Lakeland, Inc., in Lakeland, Florida - Supports medication reconciliation services provided through the pharmacy, outreach and event coordination, and outreach to homeless encampments to connect with clinical services and referrals for mental health care, patient transportation, and education.
- Cape Volunteers in Medicine in Cape May Court House, New Jersey - Improves mental and behavioral health access and treatment among at-risk populations by expanding depression and anxiety screenings. Funding will also support community events to identify community members' mental and physical needs.
- Bergen Volunteer Medical Initiative, Inc., in Hackensack, New Jersey - Increases capacity and fills a much-needed gap in care for Spanish-speaking patients with depression and anxiety through the support of a bilingual mental health practitioner.
- Parker Family Health Center in Red Bank, New Jersey - Supports a collaboration with the Mental Health Association of Monmouth County, which allows for a bilingual therapist to offer weekly counseling and the creation of mental health education to be shared at live community events, virtually, and digitally.
- Samaritan House in San Mateo, California - Samaritan House in San Mateo, California - Expands existing mental health services to include a traineeship program for students pursuing advanced degrees in marriage and family therapy or social work. The program also aims to strengthen collaboration with community organizations that provide more specialized care, develop educational resources, and offer comprehensive services to patients with depression and anxiety.
- Symba Center in Apple Valley, California - Supports successful, trauma-informed, mental and behavioral health care at a homeless shelter site.
- Westminster Free Clinic in Thousand Oaks, California - Offers a range of mental health services, including individual and peer support, and a training program that empowers parents to identify the early signs of mental health issues.
- Lestonnac Free Clinic in Orange, California - Supports a licensed clinical social worker and programs to provide care through a trauma-informed lens, who will also supervise and mentor interns from local colleges and universities.
- Savie Health in Lompoc, California - Provides culturally sensitive resources and referrals tohelp patients overcome barriers to mental health care through bilingual community health workers.
About Direct Relief
A humanitarian organization committed to improving the health and lives of people affected by poverty and emergencies, Direct Relief delivers lifesaving medical resources throughout the U.S. and world to communities in need—without regard to politics, religion, or ability to pay. For more information, visit https://www.DirectRelief.org.
About National Association of Free and Charitable Clinics
National Association of Free and Charitable Clinics (NAFC) is the only nonprofit 501c (3) organization whose mission is solely focused on the issues and needs of the medically underserved throughout the nation and the more than 1,400 Free and Charitable Clinics that serve them. The NAFC has earned the Platinum Seal of Transparency from GuideStar and a 4-star rating from Charity Navigator. Founded in 2001 and headquartered near Washington, D.C., the NAFC is working to ensure that the medically underserved have access to affordable quality health care and strives to be a national voice promoting quality health care for all. For more information about the NAFC, please visit www.nafcclinics.org.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) has been developing and producing medicines to improve people’s lives for more than a century. We are a global leader in generic, biosimilar and specialty medicines with a portfolio consisting of over 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day, and are served by one of the largest and most complex supply chains in the pharmaceutical industry. Along with our established presence in generics, we have significant innovative research and operations supporting our growing portfolio of specialty and biopharmaceutical products. Learn more at www.tevapharm.com.
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on Teva’s management current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to impact and effectively execute on our social, economic, environment and governance related strategies and goals; our ability to satisfy the targets set forth in our sustainability-linked senior notes and in other sustainability-linked financing instruments that we may issue; and the impact of ESG issues on our business; our ability to successfully compete in the marketplace, including: that we are substantially dependent on our generic products; our substantial indebtedness; our business and operations in general, including: uncertainty regarding the COVID-19 pandemic and the governmental and societal responses thereto, costs and delays resulting from the extensive pharmaceutical regulation to which we are subject or delays in governmental processing time due to travel and work restrictions caused by the COVID-19 pandemic, the effects of reforms in healthcare regulation and reductions in pharmaceutical pricing, reimbursement and coverage; compliance, regulatory and litigation matters, including: failure to comply with complex legal and regulatory environments, increased legal and regulatory action in connection with public concern over the abuse of opioid medications and our ability to reach a final resolution of the remaining opioid-related litigation; scrutiny from competition and pricing authorities around the world, including our ability to successfully defend against the U.S. Department of Justice criminal charges of Sherman Act violations; potential liability for patent infringement; product liability claims; failure to comply with complex Medicare and Medicaid reporting and payment obligations; and compliance with anti-corruption sanctions and trade control laws; other financial and economic risks; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2022 and in our Annual Report on Form 10-K for the year ended December 31, 2021, including in the sections captioned “Risk Factors” and “Forward-Looking Statements” and in our other reports that we file with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
Source: Teva Pharmaceutical Industries Limited